Search clinical trials for: RAD001 (Everolimus)

Total 1061 results

San Giuseppe Moscati Hospital

Completed

Everolimus Stent in Myocardial Infarction (RaCES-MI)

Acute Myocardial Infarction

Italy
National Cancer Institute (NCI)

Terminated

Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer

Renal Cancer | Birt-Hogg-Dube Syndrome

United States
Instituto de Urologia e Nefrologia

Unknown

Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study

Left Ventricular Hypertrophy

Brazil
Sidnei Epelman

Unknown

Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma

Refractory or Relapsed Osteosarcoma

Brazil
Sidnei Epelman

Unknown

Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas

Refractory or Relapsed RMS and Soft Tissue Sarcomas

Brazil
Novartis Pharmaceuticals

No longer available

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

Metastatic Renal Cell Cancer

United States, United Kingdom, Czech Republic, Canada, Germany, Lebanon, Turkey, Hungary, Norway, Australia, Austria, Belgium, Switzerland
NCIC Clinical Trials Group

Completed

Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme

Brain and Central Nervous System Tumors

Canada
Chang Gung Memorial Hospital

Completed

Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient

Liver Transplantation

Taiwan
Pfizer
Novartis; Keyrus Biopharma

Completed

OPALINE : A Study Of Morbidity And Mortality At 2 Years (OPALINE)

Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive

France
Novartis Pharmaceuticals

Completed

Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.

Neoplasms

Japan
Hans J. van der Vliet, MD, PhD
Novartis; Dutch Cancer Society

Completed

Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer

Metastatic Renal Cell Cancer

Netherlands
University of Kansas
Novartis

Withdrawn

A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer

Breast Cancer
University of Bologna

Unknown

Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy (PROTECT)

Heart Transplantation | Cytomegalovirus Infection | Cardiac Allograft Vasculopathy

Italy
Samsung Medical Center
Genoss Company Limited, Suwon, Korea

Recruiting

GENOSS Coronary Stent Clinical Trial

Ischemic Heart Disease

Korea, Republic of
Novartis Healthcare A/S

Completed

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Breast Cancer

Denmark
Novartis Pharmaceuticals

Completed

Everolimus in de Novo Heart Transplant Recipients (EVERHEART)

Cardiac Transplantation

Italy
National Taiwan University Hospital

Terminated

De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction

Renal Insufficiency

Taiwan
Catholic University of the Sacred Heart

Completed

SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis (SEA-SIDE)

Coronary Artery Disease | Coronary Stenosis

Italy
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals

Completed

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

Bladder Cancer | Metastatic Transitional Cell Carcinoma

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen

Renal Transplantation

Switzerland
Kidney Cancer Research Bureau

Completed

Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment

Metastatic Renal Cell Carcinoma

Russian Federation
Milton S. Hershey Medical Center
Novartis

Terminated

Trial of RAD001 in Triple Negative Metastatic Breast Cancer

Breast Cancer

United States
Hanmi Pharmaceutical Company Limited

Recruiting

A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients With Essential Hypertension (HM_APOLLO)

Hypertension

Korea, Republic of
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Treatment-naive Advanced Non-small Cell Lung Cancer

China
Rejuven Dermaceutical Co., Ltd.

Completed

RJV001 Study in Adults Receiving Abdominoplasty

Submental Fat (SMF) | Double Chin

United States
Hutchison Medipharma Limited

Recruiting

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

Advanced Renal Cell Carcinoma

China
Biotronik, Inc.
Medstar Health Research Institute; Biotronik AG; Baim Institute for Clinical...

Completed

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions (BIOFLOW-V)

Myocardial Ischemia | Coronary Artery Disease | Angina Pectoris | Acute Coronary Syndrome | Ischemic Heart Disease | Atherosclerosis, Coronary

Belgium, Israel, Spain, Korea, Republic of, United States, Switzerland, Germany, Canada, Netherlands, Hungary, Denmark, New Zealand, Australia
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Neoplasms | Kidney Neoplasms | Breast Neoplasms | Pancreatic Neuroendocine Neoplasms (pNETs)

France, Germany, United States, Netherlands, Italy, Spain, United Kingdom, Hong Kong, Hungary
University Hospital Inselspital, Berne
University of Bern; Biotronik AG

Completed

Sirolimus-eluting Stents With Biodegradable Polymer Versus an Everolimus-eluting Stents

Myocardial Infarction | Coronary Artery Disease | Angina Pectoris

Switzerland
Spanish Society of Cardiology

Completed

A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study

Myocardial Infarction

Spain, Italy, Netherlands
Hoosier Cancer Research Network
Bionomics Limited

Completed

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma

United States, Australia, Singapore
Celularity Incorporated
Celgene Corporation

Terminated

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke

Stroke, Acute | Middle Cerebral Artery Stroke | Posterior Cerebral Artery Stroke

United States
Shanghai MicroPort Medical (Group) Co., Ltd.

Active, not recruiting

Firehawk™ Coronary Stent System in the Treatment of Coronary Chronic Total Occlusion Lesion(s)

Percutaneous Coronary Intervention | Drug-Eluting Stents | Tomography, Optical Coherence

China
Hyogo College of Medicine

Withdrawn

Assessment of Stent Strut Coverage and Endothelial Function After Drug-Eluting Stents (ASSESS)

Coronary Artery Disease | Atherosclerosis

Japan
Chulalongkorn University
Ratchadapiseksompotch Research Fund

Completed

Pharmacokinetic of Everolimus and Atorvastatin Co-administration

Difference of 12-hour AUC

Thailand
Fundación Médica para la Investigación y Desarrollo...
Abbott Medical Devices; Hospital San Carlos, Madrid; B.Braun Surgical SA

Unknown

RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent) (RIBS IV)

In-stent Restenosis

Spain
Chong Kun Dang Pharmaceutical

Recruiting

Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients (STELLA)

Liver Transplant

Korea, Republic of
Children's Hospital Medical Center, Cincinnati
Novartis

Completed

A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)

Glioblastoma | Malignant Glioma of Brain | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Brainstem Glioma | Bithalamic High Grade Glioma

United States
University of Cologne

Completed

Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT (OCTET-Ever)

Graft-versus-Host Disease

Germany
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease

Germany, Austria, France
German Heart Institute
Novartis

Unknown

Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation

Coronary Artery Disease | Coronary Restenosis

Germany
Herbert Hurwitz
Novartis; Genentech, Inc.

Completed

Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors (BEL)

Advanced Solid Tumors

United States
Sahajanand Medical Technologies Pvt. Ltd.
Cardialysis BV

Terminated

SERIES III RUN-IN Clinical Trial: A Comparison of the Supralimus® Stent With the Xience V™ Stent

Coronary Artery Disease

India, Brazil, Saudi Arabia
Fundación Médica para la Investigación y Desarrollo...
Abbott Medical Devices; Hospital San Carlos, Madrid; B.Braun Surgical SA

Unknown

RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent) (RIBS V)

In-Stent Restenosis

Spain
National Institute on Drug Dependence, China
Peking University; Shengjing Hospital

Recruiting

Adjunctive Everolimus Treatment of Refractory Epilepsy

Epilepsy

China
Adam Lerner
Novartis

Terminated

Everolimus in Treating Cutaneous T-cell Lymphoma (CTCL)

Cutaneous T-Cell Lymphoma

United States
Azienda Ospedaliera di Padova

Unknown

Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study (EPOCAL)

Liver Diseases | Liver Failure | Liver Cirrhosis | Liver Neoplasms

Italy
Revance Therapeutics, Inc.

Completed

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

Facial Wrinkles | Lateral Canthal Lines | Crow's Feet

United States
TopAlliance Biosciences
Shanghai Junshi Bioscience Co., Ltd.; CTI Clinical Trial and Consulting Services

Recruiting

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Metastatic Solid Tumor | Advanced Unresectable Solid Tumor

United States
Regor Pharmaceuticals Inc.

Terminated

A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States

Search clinical trials for: RAD001 (Everolimus)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations